[바이오사 리포트] 알테오젠, 기대 밑돈 1Q…ALT-B4 이벤트 지속

Alteogen's transition from speculative licensing deals to tangible commercialization revenue signifies a critical maturation phase for its ALT-B4 platform. While Q1 earnings temporarily missed expectations due to revenue recognition timing, the platform's expansion into ADC and high-dose biologics through strategic partnerships secures its long-term dominance in the subcutaneous injection market.